As part of the federal process to address its money troubles, the beleaguered biotech firm is looking to sell off its assets.

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

In search of better sleep, one writer tests out a new science-backed service that introduces marijuana skeptics to their ...

In a heart-rending discovery, the mother, from a remote province in Peru, learned about something devastating that had ...

In a heartbreaking discovery, the mother, from a remote province in Peru, learned about something devastating that had ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Maryland's Attorney General advises deleting 23andMe accounts as bankruptcy raises concerns about the future of consumers' ...

One leading botanist is scouring remote corners of the earth to find new species that could keep our mugs full ...

Data breaches can lead to dire consequences. Here, we've unpacked the biggest fines, penalties, and shutdowns in history.

Mpox, once a rare virus mainly confined to parts of Central Africa, is rapidly evolving into a more serious global health ...

The US Federal Trade Commission (FTC) on Monday warned genetic testing firm 23andMe to honor its promise to protect people's ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen ...